← 返回

间充质干细胞来源的 IL-6 通过 JAK-STAT3 信号通路促进口腔鳞状细胞癌的侵袭和转移

英文原题:Mesenchymal stem cells-derived IL-6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK-STAT3 signalling.

查看英文原题

Mesenchymal stem cells-derived IL-6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK-STAT3 signalling.

PubMed 2023/05/30(内容时间) Oral Dis Q1 · IF 3.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

结果表明,MSCs 来源的 IL-6 通过 JAK-STAT3 信号通路促进肿瘤侵袭和转移。通过 tocilizumab 阻断该通路可能是改善 OSCC 患者预后和生存率的潜在治疗方法。

研究思路结论见上方概要

口腔鳞状细胞癌(OSCC)常伴有颈部淋巴结转移。间充质干细胞(MSCs)和白细胞介素-6(IL-6)信号被认为在促进肿瘤恶性进展中发挥重要作用。MSCs与IL-6之间详细的生物学相互作用及其对OSCC转移的后续影响在很大程度上仍不清楚。本研究旨在确定MSCs来源的IL-6对肿瘤侵袭和转移的影响及其分子机制。

在体外检测了MSC来源的IL-6和tocilizumab对OSCC细胞增殖、迁移和上皮-间质转化(EMT)的影响及潜在通路。此外,构建了小鼠异种移植模型以在体内验证其生物学机制。

结果显示,MSCs和EMT相关信号在低分化OSCC组织中的表达增加。MSCs释放更高水平的IL-6,并促进OSCC细胞和实体肿瘤的增殖、侵袭和转移,这些过程由下游分子JAK和STAT3激活。

展开英文摘要原文

Oral squamous cell carcinoma (OSCC) is often diagnosed with cervical lymph node metastasis. Mesenchymal stem cells (MSCs) and interleukin-6 (IL-6) signalling are considered to play important roles in promoting tumour malignancy. The detailed biological interaction of MSCs and IL-6 and the subsequent effect on OSCC metastasis remain largely unclear. This study aimed to determine the effects and molecular mechanism of MSCs-derived IL-6 on tumour invasion and metastasis. SUBJECTS AND METHODS: The effects of MSC-derived IL-6 and tocilizumab on the proliferation, mobility, and epithelial-mesenchymal transition (EMT) of OSCC cells and potential pathways were detected in vitro. In addition, a murine xenograft model was generated to verify the biological mechanism in vivo.

The results showed that the expression of MSCs and EMT-related signals was increased in poorly differentiated OSCC tissues. MSCs released a higher level of IL-6 and promoted the proliferation, invasion, and metastasis of OSCC cells and solid neoplasms, which were activated by the downstream molecules JAK and STAT3.

The results indicated that MSCs-derived IL-6-promoted tumour invasion and metastasis via JAK-STAT3 signalling. Blockade of this pathway by tocilizumab may be a potential treatment to improve the prognosis and survival rate of patients with OSCC.

论文信息

作者
Liu C、Zhou J、Zhang S、Fu J、Li Y、Hao Y、Yuan J、Tang F
单位
Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, China.China
文献类型
非美国政府资助研究
期刊
Oral diseases2024 May
原文标识
PubMed 37249062 · DOI 10.1111/odi.14617